Tag: Pfizer

Published by: The Canadian Press
Published on: August 22, 2025
By Nicole Ireland

TORONTO – Health Canada has authorized updated COVID-19 vaccines by Pfizer and BioNTech and by Moderna for use this respiratory virus season.

Moderna says it will manufacture vaccine doses for the Canadian market in its new facility in Laval, Quebec and syringes will be filled in Cambridge, Ontario.

News releases from both Pfizer and Moderna say the new mRNA shots will target the LP.8.1 variant, a descendant of Omicron that the World Health Organization was monitoring earlier this year.

Comments closed

vaccines

Pfizer Canada and BioNTech Receive Health Canada Approval of LP.8.1 Variant Adapted COVID-19 Vaccine

Published August 18, 2025

Published by: CNW
Published on: August 18, 2025
By Pfizer Canada Inc.

LP.8.1 variant adapted COVID-19 vaccine COMIRNATY is now authorized in Canada for individuals 6 months of age and older. It is expected to be available in Canada in the coming weeks.

KIRKLAND, QC, Aug. 18, 2025 /CNW/ – Pfizer Canada ULC and BioNTech SE (Nasdaq: BNTX) “BioNTech” announced today that Health Canada has authorized the LP.8.1 variant adapted COMIRNATY^® COVID-19 vaccine for individuals aged 6 months and older. The updated COMIRNATY^® vaccine targets the Omicron LP.8.1 variant, one of the most recently circulating SARS-CoV-2 lineages.

This season’s Pfizer and BioNTech COVID-19 vaccine will be available in pharmacies across the country in the fall. The public program operates according to the eligibility criteria determined by each province. If an individual meets these criteria, they will be eligible to receive the vaccine for free.

Comments closed

vaccines

VA study: Pfizer COVID booster 68% effective against hospitalization

Published May 2, 2025

Published by: CIDRAP
Published on: May 2, 2025
By Stephanie Soucheray

A study published earlier this week in Nature Communications using claims data from the US Veterans Affairs (VA) Healthcare System finds protection from the 2024-25 Pfizer COVID-19 vaccine was 68%, 57%, and 56% against COVID-19–associated hospitalizations, emergency department and urgent care (ED/UC) visits, and outpatient visits, respectively.

However, the authors caution that uptake of the vaccine was extremely low—only 3.7% through November 2024—and the study did not assess waning effectiveness.

The study estimated early BNT162b2 KP.2 (2024-25 formulation) vaccine effectiveness (VE) against COVID-19 outcomes compared to not receiving the vaccine.

Comments closed

anti-vaxxers

Health secretary RFK Jr. declares certain vaccines have ‘never worked,’ flummoxing scientists

Published April 10, 2025

Published by: STAT
Published on: April 10, 2025
By Helen Branswell

Health secretary Robert F. Kennedy Jr. has expressed another unorthodox view on vaccines, with the long-time vaccine critic declaring that vaccines for respiratory bugs that target a sole part of the pathogen they are meant to protect against do not work.

The claim was dismissed as erroneous by vaccine experts, who were befuddled by the secretary’s theory, espoused during an interview with CBS News.

Kennedy made the claim in explaining a controversial recent decision by political appointees at the Food and Drug Administration to delay granting a full license to Novavax’s Covid-19 vaccine, which is still given under an emergency use authorization or EUA.

Comments closed

vaccines

COVID-19 boosters start rolling out to some Canadians. Who can get them?

Published October 4, 2024

Published by: Global News
Published on: October 4, 2024
By Saba Aziz

Updated COVID-19 vaccines are starting to roll out to some high-risk Canadians, but others will have to wait a little while longer before these new shots are offered to them.

Last month, Health Canada approved Pfizer and Moderna’s latest COVID-19 vaccines targeting the most recent variants of the virus.

Both shots are approved for everyone aged six months and older.

The new mRNA vaccines from both pharmaceutical companies target the KP.2 subvariant of Omicron that was dominating COVID-19 spread earlier this year.

Comments closed

vaccines

For Canadians seeking a non-mRNA COVID vaccine, lack of Novavax shot is ‘unfair,’ advocates say

Published October 3, 2024

Published by: CTV News / The Canadian Press
Published on: October 3, 2024
By Hannah Alberga, Nicole Ireland

The federal government’s decision to not provide Novavax’s COVID-19 vaccine this respiratory virus season raises health equity concerns, experts and advocates say, as some Canadians look to the U.S. to get the shot.

The Public Health Agency of Canada said it won’t provide the protein-based vaccine called Nuvaxovid because the manufacturer required a minimum order that far exceeds last year’s uptake of the vaccine.

The health agency said 125,000 Nuvaxovid doses were ordered in 2023, but only 5,529 were administered. This fall, it will only supply provinces and territories with the reformulated Pfizer-BioNTech and Moderna mRNA COVID-19 vaccines.

But some Canadians who say they are immunocompromised and have had adverse reactions to the mRNA vaccines are calling the decision unfair.

Comments closed

vaccines

Canadian government not ordering Novavax’s protein-based COVID-19 vaccine this year

Published October 1, 2024

Published by: The Canadian Press
Published on: October 1, 2024
By Nicole Ireland

TORONTO – The Public Health Agency of Canada says it is not providing Novavax’s COVID-19 vaccine this respiratory virus season, citing low demand.

It says the manufacturer requires a minimum order of its updated protein-based vaccine, called Nuvaxovid, which far exceeds the uptake by Canadians last year.

The agency says a very small portion of the doses ordered in 2023 were used and that its decision reflects efforts to limit vaccine wastage.

It is distributing two mRNA vaccines — made by Pfizer-BioNTech and Moderna — that are approved for adults and children six months and older.

Comments closed

vaccines

Health Canada approves Pfizer-BioNTech’s updated COVID-19 vaccine

Published September 24, 2024

Published by: The Canadian Press
Published on: September 24, 2024
By Nicole Ireland, Hannah Alberga

Health Canada approved Pfizer-BioNTech’s updated COVID-19 vaccine on Tuesday, marking its third authorization of vaccine formulations that protect against the most recently circulating variants of the virus.

Pfizer-BioNTech’s mRNA vaccine, called Comirnaty, targets the KP.2 subvariant of Omicron, replacing the previous version that targeted the XBB.1.5 Omicron subvariant.

The approval of Comirnaty follows last week’s authorization of Moderna’s updated Spikevax mRNA vaccine and Novavax’s updated protein-based vaccine, Nuvaxovid.

Comments closed

Alberta

Moderna’s updated COVID-19 vaccine is coming to Alberta, but Novavax shots are not

Published September 23, 2024

Published by: CBC News
Published on: September 23, 2024
By Jennifer Lee

With the approval of Moderna’s updated COVID-19 vaccine, doctors are hoping the shots will be available soon and Albertans will opt to roll up their sleeves to get one.

Last week, Health Canada announced it had authorized Moderna’s new formulation, which targets the recent KP.2 subvariant, and that shipments would arrive within days.

A decision on Pfizer’s new formulation is expected in the next few weeks.

Comments closed

vaccines

FDA may greenlight updated Covid-19 vaccines as soon as next week, sources say

Published August 16, 2024

Published by: CNN
Published on: August 16, 2024
By Meg Tirrell

The US Food and Drug Administration is poised to sign off as soon as next week on updated Covid-19 vaccines targeting more recently circulating strains of the virus, according to two sources familiar with the matter, as the country experiences its largest summer wave in two years.

The agency is expected to greenlight updated mRNA vaccines from Moderna and Pfizer/BioNTech that target a strain of the virus called KP.2, said the sources, who declined to be named because the timing information isn’t public. It was unclear whether the agency simultaneously would authorize Novavax’s updated shot, which targets the JN.1 strain.

The move would be several weeks ahead of last year’s version of the vaccine, which got FDA signoff on September 11.

Comments closed

vaccines

Updated COVID vaccine 71% effective against hospitalization for older adults

Published January 5, 2024

Published by: CIDRAP
Published on: January 5, 2024
By Mary Van Beusekom

The estimated effectiveness of the updated COVID-19 vaccine among people aged 60 and older in the Netherlands was 70.7% against hospitalization and 73.3% against intensive care unit (ICU) admission in fall and early winter 2023, according to a study published yesterday in Eurosurveillance.

Researchers at the National Institute for Public Health and the Environment and University Medical Center Utrecht parsed data on hospitalizations with admission dates from October to December to estimate the effectiveness of the XBB.1.5 Pfizer/BioNTech COVID-19 vaccine among recipients of at least one previous vaccination. The study included 2,050 hospitalized adults aged 60 and older, 14.4% of whom had received the 2023 COVID-19 vaccine.

Comments closed

respiratory syncytial virus

Health Canada approves RSV vaccine for maternal immunization

Published January 4, 2024

Published by: CBC News
Published on: January 4, 2024
By Jessica Wong

Health Canada has approved a new vaccine geared toward protecting two groups most severely affected by the respiratory syncytial virus (RSV): newborns, who would receive antibodies through maternal immunization, and Canadians over 60.

Pfizer Canada’s bivalent vaccine, called Abrysvo, aims to prevent lower respiratory tract disease caused by the virus.

It is the first RSV vaccine in Canada approved for use in pregnancy to provide protection for infants from birth to six months of age, and the second approved for seniors aged 60 and over.

Comments closed

vaccines

Canada has ‘sufficient supply’ of new COVID-19 vaccines amid ‘pandemic amnesia,’ experts say

Published November 9, 2023

Published by: CTV News
Published on: November 9, 2023
By Mitchell Consky

As doctors recommend new COVID-19 vaccine doses to combat the XBB.1.5 Omicron subvariant, a mutation of COVID-19 that has continued to spread despite misconceptions that the virus is in the past, officials say Canada has sufficient supply.

Comments closed

antiviral drugs

Pfizer more than doubles price of lifesaving Covid-19 medication Paxlovid as US transitions out of pandemic phase

Published October 18, 2023

Published by: CNN
Published on: October 18, 2023
By Meg Tirrell

The price of the lifesaving Covid-19 antiviral medication Paxlovid will more than double as the United States transitions out of the emergency phase of the pandemic, drugmaker Pfizer said Wednesday.

Comments closed

vaccines

Is the Novavax COVID Vaccine Better than mRNA Vaccines? What We Know So Far

Published October 16, 2023

Published by: Scientific American
Published on: October 16, 2023
By Sara Reardon

As the updated COVID vaccines roll out around the country, one more competitor has joined the mix. In early October the U.S. Food and Drug Administration authorized a new booster shot made by the company Novavax. Like the mRNA-based Pfizer and Moderna shots, it targets a SARS-CoV-2 variant, XBB.1.5, which is a descendant of Omicron.

Comments closed

Nova Scotia

Appointments for new Moderna COVID-19 vaccine now available in N.S.

Published October 6, 2023

Published by: CTV News
Published on: October 6, 2023
By Jesse Huot

Appointments are now available in Nova Scotia for a new monovalent Moderna COVID-19 vaccine, which the provincial government says provides the best protection against the latest strain of the virus.

Comments closed

vaccines

Pfizer’s updated COVID vaccine approved by Health Canada

Published September 28, 2023

Published by: Global News
Published on: September 28, 2023
By Katie Dangerfield

Pfizer’s updated COVID-19 vaccine for the upcoming fall and winter months has been granted Health Canada approval.

Pfizer’s updated vaccine is approved for people six months and older.

Comments closed

vaccines

Health Canada authorizes updated Pfizer-BioNTech COVID vaccine

Published September 28, 2023

Published by: The Globe and Mail / The Canadian Press
Published on: September 28, 2023

Health Canada has authorized Pfizer-BioNTech’s updated COVID-19 vaccine for people six months and older.

The mRNA vaccine targets the Omicron XBB.1.5 subvariant that is circulating in Canada.

Comments closed

Tag: Pfizer

Still COVIDing Canada Posts

Still COVIDing Canada Posts

Still COVIDing Canada Posts

Still COVIDing Canada Posts

Still COVIDing Canada Posts

Still COVIDing Canada Posts

Still COVIDing Canada Posts

Still COVIDing Canada Posts

Still COVIDing Canada Posts

Still COVIDing Canada Posts

Still COVIDing Canada Posts

Still COVIDing Canada Posts

Still COVIDing Canada Posts

Still COVIDing Canada Posts

Still COVIDing Canada Posts

Still COVIDing Canada Posts

Still COVIDing Canada Posts

Still COVIDing Canada Posts